http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Kittinun Leetanaporn (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Ekasak Thiangphak,Kittinun Leetanaporn,Rakchai Buhachat 대한산부인과학회 2023 Obstetrics & Gynecology Science Vol.66 No.5
Objective This study evaluated the association between pretreatment total lymphocyte count (TLC) and overall survival (OS) in patients with recurrent cervical cancer. Methods We retrospectively reviewed 290 patients with recurrent cervical cancer with definite complete responses to either definitive radiotherapy or concurrent chemoradiotherapy between January 2009 and December 2022. The associations between pretreatment TLC and progression-free survival (PFS) and OS rates were evaluated. Results Ninety-three patients (32%) had a pretreatment TLC <1,000 cells/mm3. Patients with a pretreatment TLC <1,000 cells/mm3 had lower treatment response rates than their counterparts (P=0.045). The OS and PFS rates were significantly higher in patients with pretreatment TLC ≥1,000 cells/mm3 than in those with pretreatment TLC <1,000 cells/mm3 (10.74 vs. 3.89 months, P<0.0001; 8.32 vs. 4.97 months, P=0.042; respectively). Moreover, pretreatment TLC ≥1,000 cells/mm3 was identified as an independent prognostic factor for OS in both univariate analysis (hazard ratio [HR], 0.57; 95% conficence interval [CI], 0.44-0.74; P<0.001) and multivariate analysis (HR, 0.64; 95% CI, 0.47-0.86; P=0.003). However, TLC ≥1,000 cells/mm3 was identified as a prognostic factor for PFS only in univariate analysis (HR, 0.71; 95% CI, 0.51-0.99; P=0.043) but not in the multivariate analysis (HR, 0.81; 95% CI, 0.55-1.18; P=0.3). Conclusion Pretreatment TLC was associated with treatment response and was identified as an independent prognostic factor associated with the survival outcomes of patients with recurrent cervical cancer.
-
Jitti Hanprasertpong,Ingporn Jiamset,Alan Geater,Kittinun Leetanaporn,Thanarpan Peerawong 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.4
Objective: To determine the impact of time interval (TI) from radical hysterectomy with pelvicnode dissection (RHND) to adjuvant therapy on oncological outcomes in cervical cancer. Methods: The study included 110 stage IA2–IB1 cervical cancer patients who underwentRHND and adjuvant therapy. The patients were divided into 2 groups based on the cut-offpoints of TI of 4 and 6 weeks, respectively. The associations of TI and clinicopathologic factorswith oncological outcomes were evaluated using Cox proportional-hazards regression. Results: The median TI was 4.5 weeks. There were no statistical differences in 5-yearrecurrence-free survival (RFS) (89.2% vs. 81.0%, and 83.2% vs. 100.0%) or 5-year overallsurvival (OS) rates (90.9% vs. 97.2%, and 93.2% vs. 100.0%) between patients accordingto TI (≤4 vs. >4, and ≤6 vs. >6 weeks, respectively). Deep stromal invasion (p=0.037), andparametrial involvement (PI) (p=0.002) were identified as independent prognostic factorsfor RFS, together with the interaction between TI and squamous cell carcinoma histology(p<0.001). In patients with squamous cell carcinoma, a TI longer than 4 weeks wassignificantly associated with a worse RFS (hazard ratio [HR]=15.8; 95% confidence interval[CI]=1.4–173.9; p=0.024). Univariate analysis showed that only tumor size (p=0.023), and PI(p=0.003) were significantly associated with OS. Conclusion: Delay in administering adjuvant therapy more than 4 weeks after RHND in earlystage squamous cell cervical cancer results in poorer RFS.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
